Sorafenib

製品コードS7397 別名:BAY 43-9006

Sorafenib化学構造

分子量(MW):464.82

Sorafenib is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in cell-free assays, respectively.

サイズ 価格(税別)  
JPY 24402.00
JPY 44820.00
JPY 111220.00

文献中の使用例(62)

カスタマーフィードバック(9)

  • Inhibition of the MAPK signaling pathway results in downregulation of Plk-1 protein expression. (a) WB analysis for Plk-1 protein after treatment of human melanoma cell lines M14 and WM-115 with MEK 1/2 inhibitor PD98059 (10 μM), JNK inhibitor (16 μM), p38 inhibitor SB203580 (20 μM), and multikinase inhibitor sorafenib (10 μM) for 48 h showing significant reduction in the expression of Plk-1 protein after 48 hours. (b) Annexin V/PI staining of cells treated with MAPK inhibitors and induction of apoptosis. JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated protein kinase; MEK 1/2, mitogen-activated protein kinase kinase 1/2; Plk-1, polo-like kinase 1; WB, western blot.

    J Invest Dermatol 2011 131, 1886–1895. Sorafenib purchased from Selleck.

    (A) were exposed to 200 uM gentamicin for various time periods. Immunoreactivity for phosphorylated JNK (green) and c-Jun (blue) in hair cells increased in a time-dependent manner. B. Hair cells from explants pre-treated with 500 nM sorafenib displayed a near complete inhibition of JNK activation at all time points analyzed.

    J Neurosci 2013 33(7), 3079-93. Sorafenib purchased from Selleck.

  • Sorafenib in combination with metformin or the AMPK activator salicylate enhances AMPK activation. a, b, AMPK activation with the combination of sorafenib and metformin in LKB1 mutant KRAS mutant (A549 and H460) NSCLC cells (a), LKB1 wild-type KRAS mutant (H358) (b, left panel) or LKB1 mutant KRAS wild-type (H838) NSCLC cells (b, right panel). Cells were treated for 48 hr with sorafenib (1-3 uM), metformin (1–1.5 mM) or the combination of sorafenib and metformin with the same concentrations as were used for the individual treatments. c, AMPK activation with the combination of sorafenib and salicylate in LKB1 mutant KRAS mutant (A549 and H460) or LKB1 mutant KRAS wild-type (H838) NSCLC cells. Cells were treated for 48 hr with sorafenib (1–3 uM), salicylate (1–1.5 mM) or the combination of sorafenib and salicylate with the same concentrations as were used for the individual treatments. Cell lysates were harvested for western blot analysis and probed with the indicated antibodies.

    Int J Cancer 2012 10.1002/ijc.29113.. Sorafenib purchased from Selleck.

    Involvement of EV linc-VLDLR in tumor cell responses to chemotherapy. Cells were incubated with sorafenib, camptothecin, or doxorubicin. EVs were obtained after 24 hours, and qRT-PCR was performed for linc-VLDLR. The bars represent the mean ?SEM of the increase in cell viability from 3 independent studies. *, P < 0.05.

    Mol Cancer Res 2014 12(10), 1377-87. Sorafenib purchased from Selleck.

  • HCC cell-derived exosomes reverse sorafenib-induced apoptosis in hepatoma carcinoma cells in vivo. a Tumors from mice treated with PBS (Control), sorafenib (Sora), sorafenib + LO2-exosomes (Sora + LO2 exo), sorafenib + MHCC-97 L-exosomes (Sora + 97 L exo), and sorafenib + MHCC-97H-exosomes (Sora + 97H exo) were paraffin-embedded and sectioned, followed by staining of apoptotic cell by using TUNEL assays.

    J Exp Clin Cancer Res, 2016, 35(1):159. Sorafenib purchased from Selleck.

    Sorafenib and PX-866 interact to suppress tumor growth in vivo. Mice were PO administered vehicle diluent, sorafenib (25 mg/kg), PX-866 (2 mg/kg), or the drug combination QD for 3 days. Animals were monitored daily and tumor volume determined every fifth day. Tumors from animals were isolated at day 15 and fixed, sectioned (10-um), and stained against proliferation (Ki67 staining), phospho-ERK1/2 and phospho-AKT staining, the levels of tumor cell apoptosis/cleaved caspase 3, as well as with H&E and 4′,6-diamidino-2-phenylindole (DAPI).

    Mol Pharmacol 2013 84(4), 562-71. Sorafenib purchased from Selleck.

  • Effects of sorafenib or sunitinib on LicA-induced cell death, ER stress responses, PLCc1, Ca2+, and ROS in HepG2 cells. HepG2 cells were pretreated with sorafenib or sunitinib for 1 h, then treated with LicA or TG for 1 h (for P-eIF2a and P-PLCc1) or 24 h (for CHOP, ATF6a(p90), and caspase-4). The cell lysates were subjected to Western blot analyses using antibodies against CHOP, ATF6a(p90), caspase-4(C), P-eIF2a, and b-actin.

    Apoptosis 2014 19(4), 682-97. Sorafenib purchased from Selleck.

    PLoS One 2013 8(1), e54595. Sorafenib purchased from Selleck.

  • (C) Western blotting revealed the expression levels of p-AKT, p-ERK1/2 and cleaved PARP in HUH-7 and R-HUH-7 HCC cell lines, these cell lines were treated with three different concentrations of sorafenib (0, 5, and 10 μM) for 24 h. (D) Western blotting revealed the expression levels of p-AKT, p-ERK1/2 and cleaved PARP in SK-HEP-1 and R-SK-HEP-1 HCC cell lines, these cell lines were treated with three different concentrations of sorafenib (0, 5, and 10 μM) for 24 h. (E) HUH-7 hepatoma cells treated with three different concentrations of sorafenib (0, 5, and 10 μM) for 24 h; proportions of apoptotic cells were calculated after cell cytotoxicity assay. (F) SK-HEP-1 hepatoma cells treated with three different concentrations of sorafenib (0, 5, and 10 μM) for 24 h; proportions of apoptotic cells were calculated after cell cytotoxicity assay. Data were expressed as mean ± standard deviation of each experiment in triplicate. (*P < 0.05, HUH-7, SK-HEP-1 are control groups, R-HUH-7, R-SK-HEP-1 are resistant groups).

    J Surg Res, 2016, 206(2):371-379. Sorafenib purchased from Selleck.

製品安全説明書

Raf阻害剤の選択性比較

生物活性

製品説明 Sorafenib is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in cell-free assays, respectively.
ターゲット
Raf-1 [1]
(Cell-free assay)
mVEGFR2(Flk1) [1]
(Cell-free assay)
mVEGFR3 [1]
(Cell-free assay)
B-Raf [1]
(Cell-free assay)
B-Raf (V599E) [1]
(Cell-free assay)
6 nM 15 nM 20 nM 22 nM 38 nM
体外試験

Sorafenib inhibits both wild-type and V599E mutant B-Raf activity with IC50 of 22 nM and 38 nM, respectively. Sorafenib also potently inhibits mVEGFR2 (Flk-1), mVEGFR3, mPDGFRβ, Flt3, and c-Kit with IC50 of 15 nM, 20 nM, 57 nM, 58 nM, and 68 nM, respectively. Sorafenib weakly inhibits FGFR-1 with IC50 of 580 nM. Sorafenib tosylate is not active against ERK-1, MEK-1, EGFR, HER-2, IGFR-1, c-Met, PKB, PKA, cdk1/cyclinB, PKCα, PKCγ, and pim-1. Sorafenib markedly inhibits VEGFR2 phosphorylation in NIH 3T3 cells with IC50 of 30 nM, and Flt-3 phosphorylation in HEK-293 cells with IC50 of 20 nM. Sorafenib potently blocks MEK 1/2 and ERK 1/2 phosphorylation in most cell lines but not in A549 or H460 cells, while having no effect on inhibition of the PKB pathway. Sorafenib inhibits the proliferation of HAoSMC and MDA-MB-231 cells with IC50 of 0.28 μM and 2.6 μM, respectively. [1] In addition to inhibition of the RAF/MEK/ERK signaling pathway, Sorafenib significantly inhibits the phosphorylation of eIF4E and down-regulates Mcl-1 levels in hepatocellular carcinoma (HCC) cells in a MEK/ERK-independent manner. Sorafenib inhibits the proliferation of PLC/PRF/5 and HepG2 cells with IC50 of 6.3 μM and 4.5 μM, respectively, and leads to the significant induction of apoptosis. [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 Mn;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1SwbmlEPTB;MD6wNFAxODNyMzFOwG0> NVTKVYQ2W0GQR1XS
MONO-MAC-6 NXrRc|ZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjifZVKSzVyPUCuNFA1OThizszN MkLuV2FPT0WU
ALL-PO NYHzOnIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTBwMEOxPFQh|ryP M3\ENXNCVkeHUh?=
NKM-1 NX\ZdoN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWK3NoVWUUN3ME2wMlA4PDF4IN88US=> NXvDUIxjW0GQR1XS
CGTH-W-1 M2nvNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTBwMkWwNlIh|ryP NXnEXYY{W0GQR1XS
BB65-RCC NIHBbHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3CbZpKSzVyPUCuOFcxPzNizszN MnjnV2FPT0WU
NOS-1 M1v1R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrnTWM2OD1yLkW2N|Yh|ryP MnvRV2FPT0WU
SH-4 Mn3hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDRUYlKSzVyPUCuOlU3OTNizszN NXLBTHlsW0GQR1XS
HOP-62 MmfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHqbpdtUUN3ME2wMlg2ODh6IN88US=> MlfNV2FPT0WU
HCC2998 NELmfo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTBwOEi4NVgh|ryP MXvTRW5ITVJ?
GDM-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHqxd4RKSzVyPUCuPVA3QThizszN NFrKSo5USU6JRWK=
KM12 NG\qcodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXZN45KSzVyPUGuNFIxQThizszN NWG4U2V[W0GQR1XS
LB2518-MEL M3vKeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkf6TWM2OD1zLkKwPFA6KM7:TR?= MlPTV2FPT0WU
NCI-H1436 M4C1WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfWTWM2OD1zLkKxOlc5KM7:TR?= MoC1V2FPT0WU
EM-2 NEeyR3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTaT4ZnUUN3ME2xMlM2PTd6IN88US=> NWDEUGc3W0GQR1XS
LAMA-84 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTFwM{e2OFgh|ryP M2q2V3NCVkeHUh?=
KG-1 Mn\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF:2bmxKSzVyPUGuOFc6OzVizszN MWnTRW5ITVJ?
A388 NF3K[VdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHkZVExUUN3ME2xMlU6OTZ3IN88US=> MoPmV2FPT0WU
no-10 NUOw[VJGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\VXGlEPTB;MT62NVczPiEQvF2= MmXjV2FPT0WU
SF126 NG\YWWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4L6RWlEPTB;MT62N|gyOiEQvF2= NUPzcppQW0GQR1XS
MEG-01 NYL6VGNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTFwOEC5PEDPxE1? NVHpW3IyW0GQR1XS
A3-KAW NH:zdWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTFwOEi0NkDPxE1? MY\TRW5ITVJ?
D-247MG MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonvTWM2OD1{LkG0OFgh|ryP MX7TRW5ITVJ?
OVCAR-4 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlf3TWM2OD1{LkKxN|k{KM7:TR?= M{HKUnNCVkeHUh?=
NCI-SNU-1 M3;nXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3DOopKSzVyPUKuN|E3OiEQvF2= NW[0coF4W0GQR1XS
NCI-H2171 NWL2c3JRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;4Uo9iUUN3ME2yMlM6PzZ2IN88US=> NGTrU|BUSU6JRWK=
SIG-M5 MlzZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTJwNEKyOFIh|ryP M{X0TnNCVkeHUh?=
BE-13 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LXfGlEPTB;Mj62PVYxQSEQvF2= NEOyOJJUSU6JRWK=
K052 NX\zOYZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHH6cFFKSzVyPUKuO|Q3OTZizszN M2S0eHNCVkeHUh?=
L-540 MmDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DETGlEPTB;Mj63OVc5QSEQvF2= Ml\mV2FPT0WU
KMOE-2 NHjBSZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTJwOEGzOUDPxE1? M{W1UHNCVkeHUh?=
MFH-ino MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHT2R4tKSzVyPUKuPVIyQDVizszN NHr4[2FUSU6JRWK=
HL-60 NFT0XZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HiS2lEPTB;Mz6wOlI6QSEQvF2= NEDVdIJUSU6JRWK=
HCC2218 NWDUSllnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfnTWM2OD1|LkGyNFA{KM7:TR?= MmHJV2FPT0WU
TE-5 Ml3MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHGdodKSzVyPUOuNVMyPjJizszN M3rU[XNCVkeHUh?=
MZ1-PC Ml\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF64WXZKSzVyPUOuOFc2ODlizszN NUjqNVR3W0GQR1XS
MRK-nu-1 MofNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTNwNkG0Olgh|ryP NELkUI9USU6JRWK=
MZ7-mel MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfyTopLUUN3ME2zMlY3ODl7IN88US=> NIrVXFdUSU6JRWK=
BC-1 M{[2c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWj0UZpYUUN3ME2zMlc1ODJizszN MVLTRW5ITVJ?
ST486 NFrqVXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjITWM2OD1|LkizOlc{KM7:TR?= MYnTRW5ITVJ?
KS-1 M1jEbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nt[WlEPTB;Mz64PFE6QCEQvF2= M3XlfHNCVkeHUh?=
SK-NEP-1 M4TTOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzCNoFKSzVyPUSuNVY5OTVizszN M4nNTXNCVkeHUh?=
BC-3 MmrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLZRW5KSzVyPUSuNlM{QTFizszN MVXTRW5ITVJ?
NCI-H1581 MmTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPTRWg4UUN3ME20MlI5Pzl6IN88US=> MkP0V2FPT0WU
MHH-PREB-1 M2DLeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTRwNEC0PFQh|ryP NYTHb45pW0GQR1XS
NOMO-1 M2HJ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\GTmlEPTB;ND60PFkxPSEQvF2= NGT1SJlUSU6JRWK=
QIMR-WIL NGLjR2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH72[mFKSzVyPUWuNFczQTRizszN NEHnNW9USU6JRWK=
SF539 M3;PS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\jd2lEPTB;NT6xN|IzPyEQvF2= NWXmPWlVW0GQR1XS
TE-12 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvQTWM2OD13LkK0PVI6KM7:TR?= MnPrV2FPT0WU
NCI-H510A MkPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHVR3dmUUN3ME21MlQyPjh3IN88US=> MkXjV2FPT0WU
JAR NYPGcWdkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;qT2lEPTB;NT61NFgzPCEQvF2= NWGzbYtIW0GQR1XS
no-11 M4e5fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIT1UIpKSzVyPUWuO|M2PjhizszN MkPRV2FPT0WU
BV-173 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13F[mlEPTB;NT65OVY5OiEQvF2= MYLTRW5ITVJ?
SR Mk\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrONmdKSzVyPU[uNFA3PzhizszN Mkf0V2FPT0WU
MOLT-16 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PLOmlEPTB;Nj6yOVI3PiEQvF2= MnHsV2FPT0WU
MZ2-MEL MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jJS2lEPTB;Nj6zNVg{QSEQvF2= MYXTRW5ITVJ?
SW954 NXfvVpZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTZwNEW4OlYh|ryP M1f3UXNCVkeHUh?=
ML-2 NFzUWGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zxcGlEPTB;Nj61Nlg1QSEQvF2= MVnTRW5ITVJ?
OCI-AML2 NX[2c49RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHjV5U5UUN3ME22MlYyODZ{IN88US=> NIfxe5ZUSU6JRWK=
SIMA M2PoRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3v1eGlEPTB;Nz6wNFExOSEQvF2= M4HBXHNCVkeHUh?=
DOHH-2 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV:zbpZqUUN3ME23MlA2Pjd4IN88US=> NY\TXXMyW0GQR1XS
697 NX3UR2YxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHuTWM2OD15LkC1PVg6KM7:TR?= M1fNZ3NCVkeHUh?=
NB1 NXfqV49PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTa[3VEUUN3ME23MlQxPDB5IN88US=> M3:0S3NCVkeHUh?=
D-392MG MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4CydGlEPTB;Nz62NlY3OyEQvF2= NWf2SmFGW0GQR1XS
ES8 M4D4S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrJb4ZWUUN3ME23Mlc3PTB|IN88US=> MmHpV2FPT0WU
RPMI-8226 NFrrd2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\OU2xKSzVyPUeuPFQ2OTFizszN NWPlUlRKW0GQR1XS
IST-MEL1 NYfPdXFQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRThwNECwNFIh|ryP NWnqb5V4W0GQR1XS
NB14 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRThwNkOxN|Mh|ryP NHH5TYRUSU6JRWK=
HD-MY-Z M3e2[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRThwNkO3OFYh|ryP MmL3V2FPT0WU
TE-10 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrocolKSzVyPUiuO|Y{PTNizszN NXTjO4MxW0GQR1XS
LC-1F NF7JbIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\2[45sUUN3ME25MlExQDN2IN88US=> MWDTRW5ITVJ?
OS-RC-2 NWTDcW16T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTlwMUGyOFMh|ryP MUHTRW5ITVJ?
NCI-SNU-16 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTlwMkGwNlYh|ryP M3fKWHNCVkeHUh?=
SHP-77 NF;S[GlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfrXVFKSzVyPUmuO|E3PjJizszN NV[3b4g2W0GQR1XS
A4-Fuk NH7FbmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTlwN{W2NUDPxE1? NVzP[IVXW0GQR1XS
NB6 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jINWlEPTB;OT63OlAzQSEQvF2= MYHTRW5ITVJ?
JiyoyeP-2003 NF7SPZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTFyLkS3OFUh|ryP M1HxRnNCVkeHUh?=
DMS-114 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\WbZkxUUN3ME2xNE42PDRzIN88US=> MW\TRW5ITVJ?
NB7 NUfvWlM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTFTWM2OD1zMD63OVI3KM7:TR?= NF3k[GZUSU6JRWK=
NCI-H747 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITFbWlKSzVyPUGxMlEzOTZizszN M2eyfXNCVkeHUh?=
HH NX31bG4{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXmTWM2OD1zMT6zPFc3KM7:TR?= MkXtV2FPT0WU
EW-18 NVjvd4ZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHqTWM2OD1zMT65NFQ1KM7:TR?= M3HzcnNCVkeHUh?=
CHP-126 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTFzLkm3N|gh|ryP MmG3V2FPT0WU
NTERA-S-cl-D1 MonHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTF{LkCyO|gh|ryP M1vLNnNCVkeHUh?=
DEL NFK4Z2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTF{LkC5PFUh|ryP Mn\aV2FPT0WU
LU-139 NXL5WGVST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTF{LkW0NVMh|ryP Mn7uV2FPT0WU
P30-OHK NFTPVnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M331bWlEPTB;MUKuOVQ4QSEQvF2= MkPuV2FPT0WU
NCI-H1522 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3kfYVKSzVyPUGyMlc1PiEQvF2= NWnsNHMyW0GQR1XS
NCI-H1299 M4Hzbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjMSFBPUUN3ME2xN{4zQTFzIN88US=> MmntV2FPT0WU
UACC-257 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoO1TWM2OD1zMz61NVI3KM7:TR?= MlTYV2FPT0WU
Calu-6 NUfTdHJlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTnN2N[UUN3ME2xN{43ODR4IN88US=> NHO1fmxUSU6JRWK=
NCI-H1882 MnfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;TboVKSzVyPUGzMlg2PTVizszN MUPTRW5ITVJ?
BB30-HNC M13NbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn76TWM2OD1zND6wOlA6KM7:TR?= NYnlfFNFW0GQR1XS
ES1 NWnveXlqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDHTWM2OD1zND6xOVUyKM7:TR?= M1TtdXNCVkeHUh?=
NCI-H1694 M2XEb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTF2LkS4NVEh|ryP MXTTRW5ITVJ?
IST-SL1 NIWwVmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPsW2xGUUN3ME2xOE46PjF4IN88US=> NHnqbVdUSU6JRWK=
ECC4 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTF3LkC1OVgh|ryP Mlv6V2FPT0WU
MDA-MB-134-VI Mm\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDEcmR1UUN3ME2xOU41OTNzIN88US=> MWLTRW5ITVJ?
SCH NGPl[YNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DqNmlEPTB;MUWuOFczQCEQvF2= NVzaU|VUW0GQR1XS
SK-N-FI M1XHNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mle5TWM2OD1zNT62OVM1KM7:TR?= NIq5ZZVUSU6JRWK=
HDLM-2 M3HxXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEO0WmRKSzVyPUG2MlA4OTRizszN NUDFNVUxW0GQR1XS
Ramos-2G6-4C10 M1r1Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;vcJE{UUN3ME2xOk4yOjl5IN88US=> MYTTRW5ITVJ?
EW-24 M1e2UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fnT2lEPTB;MU[uNVY3OSEQvF2= NUHNbo5KW0GQR1XS
NCI-H2141 NX;CZZB3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFO0Z4FKSzVyPUG2MlE5QSEQvF2= M121eHNCVkeHUh?=
LC4-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTkSpNTUUN3ME2xOk43OTF7IN88US=> MYTTRW5ITVJ?
HT-144 M4jFfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\VNmJDUUN3ME2xO{4xODZizszN MUHTRW5ITVJ?
SK-MEL-1 NHXGfodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTF5LkCwO|Ih|ryP MXzTRW5ITVJ?
SCC-15 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TxO2lEPTB;MUeuNVY{QCEQvF2= M2Tj[3NCVkeHUh?=
C8166 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTF5Lk[4N|Mh|ryP MnHXV2FPT0WU
GOTO NXLBc4xlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XifWlEPTB;MUeuPFM1PCEQvF2= M2[yZ3NCVkeHUh?=
COR-L279 NEfJSIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTF6LkGzOlIh|ryP MlrxV2FPT0WU
K-562 MlHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HmOWlEPTB;MUiuO|E1OyEQvF2= M2GzVXNCVkeHUh?=
ES3 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DkPGlEPTB;MUiuPFA1OSEQvF2= MVzTRW5ITVJ?
LU-165 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTF7LkewNFgh|ryP NV3Z[Y1bW0GQR1XS
KM-H2 NUfH[|BFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUm2ZpFWUUN3ME2yNE4{OTh2IN88US=> MXrTRW5ITVJ?
RL NHzIOJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInPdlBKSzVyPUKwMlk3QTJizszN MX7TRW5ITVJ?
EW-3 NX3aNJY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILCT|NKSzVyPUKxMlE5QDlizszN Mnf6V2FPT0WU
A101D MoniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTJzLkO3OVIh|ryP NFjH[oNUSU6JRWK=
HUTU-80 MnrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4C2UWlEPTB;MkGuN|k1PiEQvF2= Ml;jV2FPT0WU
NCI-H23 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\jTWM2OD1{MT6zPVkzKM7:TR?= M{Xhe3NCVkeHUh?=
PF-382 NHzwepNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4T4OWlEPTB;MkGuOFQxOyEQvF2= NEPme5FUSU6JRWK=
LB373-MEL-D MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M16zUmlEPTB;MkGuOVYyPSEQvF2= NYrz[ndUW0GQR1XS
TE-8 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfSN|FFUUN3ME2yNU43Ozl2IN88US=> NHjyXWVUSU6JRWK=
TE-9 NEDiZnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTJzLki1NVMh|ryP Ml\kV2FPT0WU
Daudi NWLtbpFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moq0TWM2OD1{MT65N|A1KM7:TR?= M4XuWHNCVkeHUh?=
D-542MG MkXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTJ{LkCyOVYh|ryP M3\RdHNCVkeHUh?=
U-698-M MoHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTJ{LkS2NFMh|ryP MljQV2FPT0WU
ES6 MkjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVL4RWl6UUN3ME2yNk44OzZ4IN88US=> MUHTRW5ITVJ?
DU-4475 Mm\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnZO3ZGUUN3ME2yN{45QDl5IN88US=> M1THT3NCVkeHUh?=
ECC12 NYf3S3hxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mny2TWM2OD1{ND6yPFA{KM7:TR?= NV;B[YdoW0GQR1XS
C2BBe1 MnTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXoTWM2OD1{ND6zNlM6KM7:TR?= M4TaW3NCVkeHUh?=
IST-SL2 NFj0TGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nSOGlEPTB;MkSuOFM3OiEQvF2= M1TzPXNCVkeHUh?=
DJM-1 Mn7TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTJ2LkWyNlEh|ryP NFXrcoxUSU6JRWK=
DMS-153 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nBR2lEPTB;MkSuPFYyPCEQvF2= MoLaV2FPT0WU
NB13 NH3tPXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjUTWM2OD1{NT6wNlY2KM7:TR?= M1vGXXNCVkeHUh?=
SK-N-DZ MoPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXu2Vlk{UUN3ME2yOk4{PDF2IN88US=> NX\USVFUW0GQR1XS
COR-L88 M2nwO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jHRmlEPTB;Mk[uOVc6PiEQvF2= MmTnV2FPT0WU
LU-65 NX\xSYFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3CTWM2OD1{Nj64OVM2KM7:TR?= NYPpZopXW0GQR1XS
TGBC1TKB MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLB[FE4UUN3ME2yOk46QDJ6IN88US=> NH7vV2pUSU6JRWK=
THP-1 M4LPdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTJ5LkKxOFEh|ryP M1rnVnNCVkeHUh?=
ONS-76 NFjsXm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDETGNKSzVyPUK3MlM{OiEQvF2= M1XQTnNCVkeHUh?=
LC-2-ad NE[5dmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrXRnJKSzVyPUK3MlYzOzFizszN NX3QcnpCW0GQR1XS
EW-13 NF;zRYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHUSG9YUUN3ME2yPU4yPzR4IN88US=> MWjTRW5ITVJ?
MS-1 NYrleG1[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnMTWM2OD1|MD63Nlc5KM7:TR?= NI[2UY9USU6JRWK=
NCI-H2227 MonFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTNyLkm4NFYh|ryP M1Lq[nNCVkeHUh?=
LXF-289 NXLMTYpXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LrXmlEPTB;M{GuOFQ6OiEQvF2= NWf2XFVxW0GQR1XS
MC116 MlvhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\OUGlEPTB;M{KuNFgzPiEQvF2= M1LkOXNCVkeHUh?=
EVSA-T MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnTcW1KSzVyPUOyMlI2QDVizszN M13SdXNCVkeHUh?=
CTB-1 NXPKUGdrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4CyfWlEPTB;M{OuNVExOSEQvF2= NXrHb3Z{W0GQR1XS
COLO-320-HSR NW\2WFZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPQ[WQ3UUN3ME2zN{4yPjB|IN88US=> NF\UOnhUSU6JRWK=
NCI-H2196 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTYWoN5UUN3ME2zN{4zPTV5IN88US=> NWfXdoJNW0GQR1XS
LB2241-RCC MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHraSmNKSzVyPUOzMlMyOzVizszN MW\TRW5ITVJ?
LS-513 M4[zW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTN|Lki2N|gh|ryP NWX3PJVjW0GQR1XS
LP-1 NEj2ZndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITDb21KSzVyPUOzMlk6PTZizszN MUfTRW5ITVJ?
A253 MnL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PO[mlEPTB;M{SuNlI6PiEQvF2= Mlf4V2FPT0WU
SK-MM-2 M4m4PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jWRWlEPTB;M{SuPVQ2OSEQvF2= NGm1PY5USU6JRWK=
NCI-H1963 M1nEe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW[xc|VwUUN3ME2zOU4{ODd{IN88US=> MVTTRW5ITVJ?
MMAC-SF M2DvRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHyb2t[UUN3ME2zOU45Pzh3IN88US=> MnT2V2FPT0WU
LB831-BLC MnHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTN4LkC2OVQh|ryP M3vlWHNCVkeHUh?=
WSU-NHL M1jRdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\CfI9KSzVyPUO2MlE3PCEQvF2= M{XwPHNCVkeHUh?=
CESS M1n6Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33me2lEPTB;M{[uNlg1QCEQvF2= M2PZbnNCVkeHUh?=
NEC8 MmroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDGdI41UUN3ME2zOk42QDN3IN88US=> NVGxV3U6W0GQR1XS
KNS-42 NXnKcZBQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfXWphKSzVyPUO3MlEzOzdizszN NHrmfJpUSU6JRWK=
MHH-CALL-2 NXjnTmlET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLBTWM2OD1|Nz6xPFIyKM7:TR?= Ml:wV2FPT0WU
K5 NF\ne3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXLVYFKSzVyPUO4MlQ{KM7:TR?= M1rJc3NCVkeHUh?=
CP66-MEL NXy3foppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7nTWM2OD1|OT6wO|M{KM7:TR?= MlrmV2FPT0WU
OPM-2 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVe1[4VLUUN3ME2zPU45PDN{IN88US=> NYrB[mFLW0GQR1XS
IST-MES1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PYeGlEPTB;NECuN|A6PiEQvF2= M4rxNnNCVkeHUh?=
EC-GI-10 NF7SPVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fZVWlEPTB;NEGuOVgxPSEQvF2= MWLTRW5ITVJ?
CTV-1 MlO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzKW2pXUUN3ME20Nk45PDB4IN88US=> NH\lT5JUSU6JRWK=
DG-75 NEnl[ZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHr4PYFKSzVyPUSzMlc2QTVizszN MlfLV2FPT0WU
KNS-81-FD MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUniWJhoUUN3ME20OU41ODV6IN88US=> MojaV2FPT0WU
NCI-H82 M3fifGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4C0UWlEPTB;NEWuOVc2QCEQvF2= MUTTRW5ITVJ?
RPMI-8866 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDDVFRKSzVyPUS2MlE5PzNizszN MV;TRW5ITVJ?
ACN Mmr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3QTWM2OD12Nj60N|Qh|ryP NVf3fnpLW0GQR1XS
NCI-H1395 M2W2O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYj1NoMyUUN3ME20Ok41PzV4IN88US=> NYXufGJIW0GQR1XS
NCI-H209 NI\xRXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIC3XFBKSzVyPUS3MlE1ODVizszN NV:1RpR6W0GQR1XS
TGW MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;UdnJSUUN3ME20PU4xPzlzIN88US=> NYfHR2lZW0GQR1XS
NCI-H748 MnjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTCXJVKSzVyPUS5MlQ4PTNizszN M4n5WnNCVkeHUh?=
EKVX NGrXTItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7tUZFKSzVyPUS5MlY3OjhizszN NXThbW1IW0GQR1XS

多くの細胞株試験データを見る場合、クリックしてください

体内試験 Oral administration of Sorafenib (~60 mg/kg) demonstrates broad spectrum, dose-dependent anti-tumor activity against a variety of human tumor xenograft models including MDA-MB-231, Colo-205, HT-29, DLD-1, NCI-H460, and A549, with no evidence of toxicity. In association with the anti-tumor efficacy, Sorafenib treatment potently inhibits MEK 1/2 phosphorylation and pERK 1/2 levels in HT-29 and MDA-MB-231 xenografts but not in Colo-205 xenografts, and significantly suppresses tumor microvessel area (MVA) and microvessel density (MVD) in MDA MB-231, HT-29 and Colo-205 tumor xenografts. [1] Sorafenib treatment produces dose-dependent growth inhibition of PLC/PRF/5 tumor xenografts in SCID mice with TGIs of 49% and 78% at 10 mg/kg and 30 mg/kg, respectively, consistent with the inhibition of ERK and eIF4E phosphorylation, reduction of the microvessel area, and induction of tumor cell apoptosis. [2] Sorafenib sensitizes bax-/- cells to TRAIL in a dose-dependent manner, through a mechanism involving down-regulating NF-κB mediated Mcl-1 and cIAP2 expression. Combining Sorafenib (30-60 mg/kg) with TRAIL (5 mg/kg) show dramatic efficacy in TRAIL-resistant HCT116 bax-/- and HT29 tumor xenografts. [3]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

Biochemical assays:

Recombinant baculoviruses expressing Raf-1 (residues 305–648) and B-Raf (residues 409–765) are purified as fusion proteins. Full-length human MEK-1 is generated by PCR and purified as a fusion protein from Escherichia coli lysates. Sorafenib tosylate is added to a mixture of Raf-1 (80 ng), or B-Raf (80 ng) with MEK-1 (1 μg) in assay buffer [20 mM Tris (pH 8.2), 100 mM NaCl, 5 mM MgCl2, and 0.15% β-mercaptoethanol] at a final concentration of 1% DMSO. The Raf kinase assay (final volume of 50 μL) is initiated by adding 25 μL of 10 μM γ[33P]ATP (400 Ci/mol) and incubated at 32 °C for 25 minutes. Phosphorylated MEK-1 is harvested by filtration onto a phosphocellulose mat, and 1% phosphoric acid is used to wash away unbound radioactivity. After drying by microwave heating, a β-plate counter is used to quantify filter-bound radioactivity. Human VEGFR2 (KDR) kinase domain is expressed and purified from Sf9 lysates. Time-resolved fluorescence energy transfer assays for VEGFR2 are performed in 96-well opaque plates in the time-resolved fluorescence energy transfer format. Final reaction conditions are as follows: 1 to 10 μM ATP, 25 nM poly GT-biotin, 2 nM Europium-labeled phospho (p)-Tyr antibody (PY20), 10 nM APC, 1 to 7 nM cytoplasmic kinase domain in final concentrations of 1% DMSO, 50 mM HEPES (pH 7.5), 10 mM MgCl2, 0.1 mM EDTA, 0.015% Brij-35, 0.1 mg/mL BSA, and 0.1% β-mercaptoethanol. Reaction volumes are 100 μL and are initiated by addition of enzyme. Plates are read at both 615 and 665 nM on a Perkin-Elmer VictorV Multilabel counter at ~1.5 to 2.0 hours after reaction initiation. Signal is calculated as a ratio: (665 nm/615 nM) × 10,000 for each well. For IC50 generation, Sorafenib tosylate is added before the enzyme initiation. A 50-fold stock plate is made with Sorafenib tosylate serially diluted 1:3 in a 50% DMSO/50% distilled water solution. Final Sorafenib tosylate concentrations range from 10 μM to 4.56 nM in 1% DMSO.
細胞試験:

[1]

+ 展開
  • 細胞株: MDA-MB-231, and HAoSMC
  • 濃度: Dissolved in DMSO, final concentrations ~10 μM
  • 反応時間: 72 hours
  • 実験の流れ:

    Cells are exposed to increasing concentrations of Sorafenib tosylate for 72 hours. Cell number is quantitated using the Cell TiterGlo ATP Luminescent assay kit. This assay measures the number of viable cells per well by measurement of luminescent signal based on amount of cellular ATP.


    (参考用のみ)
動物試験:

[1]

+ 展開
  • 動物モデル: Female NCr-nu/nu mice implanted s.c. with MDA-MB-231, Colo-205, HT-29, H460, or A549 cells
  • 製剤: Dissolved in Cremophor EL/ethanol (50:50) as 4-fold (4 × stock solution, and diluted to 1 × with water
  • 投薬量: ~60 mg/kg
  • 投与方法: Orally once daily
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 63 mg/mL (135.53 mM) warming
Water Insoluble
Ethanol Insoluble
体内 左から右までの手順で、溶剤を製品に加えることです:
5% DMSO+45% PEG 400+ddH2O
いい結果が出るために、混じった後、直ちに使うと推めます。
3mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 464.82
化学式

C21H16ClF3N4O3

CAS No. 284461-73-0
保管
別名 BAY 43-9006

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00727233 Completed Neurofibromatosis Type I|Plexiform Neurofibroma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 8, 2008 Phase 1
NCT02989870 Not yet recruiting HepatoCellular Carcinoma|Unresectable HepatoCellular Carcinoma|Liver Cancer H. Lee Moffitt Cancer Center and Research Institute|National Comprehensive Cancer Network April 30, 2017 Phase 1
NCT01445080 Completed Leukemia|With AML and FLT3-ITD Mutations National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) August 23, 2006 Phase 1
NCT01434602 Recruiting Brain Tumor|Glioblastoma|Anaplastic Glioma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 21, 2015 Phase 1|Phase 2
NCT02988440 Not yet recruiting Hepatocellular Carcinoma Novartis Pharmaceuticals|Novartis May 2017 Phase 1
NCT03037437 Not yet recruiting Hepatocellular Cancer The University of Texas Health Science Center at San Antonio January 2017 Phase 2

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

Related Antibodies

Rafシグナル伝達経路

相関Raf製品

Tags: Sorafenibを買う | Sorafenib ic50 | Sorafenib供給者 | Sorafenibを購入する | Sorafenib費用 | Sorafenib生産者 | オーダーSorafenib | Sorafenib化学構造 | Sorafenib分子量 | Sorafenib代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID